AzTrials
AzTrials

TB - TuberculosisKAP TBNCT07749872

KAP TB in Senior Management Officials of Companies With Increased Silica Exposure

An observational study of TB - Tuberculosis and Silicosis, run by Centre for Infectious Disease Research in Zambia at 1 site in Zambia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study was designed as a descriptive cross-sectional survey conducted between February and October 2022. Senior management officials were targeted because of their role in workplace policy and oversight. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
How many people
118 participants
Where
1 siteZambia
Study dates
2 Feb 2022to 28 Feb 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: The sample population was drawn from the Zambia Chamber of Commerce and Industry (ZACCI), an umbrella organization representing businesses across all sectors. ZACCI advocates for workplace legislation and a conducive business environment. Companies known to produce silica dust were identified under categories including mining, construction, cement manufacturing, brick and tile manufacturing, and glass and ceramic manufacturing. The sampling frame included 1 mining company, 73 construction companies, 1 cement company, 9 brick/tile companies, and 10 glass/ceramic companies. Each company was asked to nominate at least one senior official to complete the questionnaire, with a maximum of two responses per company. This ensured representation across industries while maintaining focus on individuals with policy-making authority.

Who may be able to join

  • Companies known to produce silica dust
  • members of ZACCI
  • current active senior management role

Who cannot join

  • none silica producing companies
  • junior staff

Trial locations and contacts

1 site in 1 country.

Zambia1 site
  • CIDRZ

    Lusaka, Lusaka Province, 10101

Other trials in Zambia

About this study

Official title: Knowledge, Attitude, and Practices Regarding TB Among Senior Management Officials of Companies With Increased Silica Dust Exposure in Lusaka and Southern Provinces of Zambia

The study was designed as a descriptive cross-sectional survey conducted between February and October 2022. Senior management officials were targeted because of their role in workplace policy and oversight. The sample was drawn from companies registered under the Zambia Chamber of Commerce and Industry (ZACCI), focusing on those with known silica dust exposure. Each company was asked to provide one or two senior officials to participate. A total of 118 individuals completed the survey.

Data collection was carried out using a self-administered electronic questionnaire developed in line with WHO recommendations for TB KAP surveys. The questionnaire contained 28 mandatory closed-ended questions: 7 on knowledge, 8 on attitudes, and 13 on practices (with 5 practice questions excluded from scoring as they were programmatic). Responses were validated by three medical doctors, and scoring was based on correct answers. Knowledge, attitude, and practice scores were categorized into "poor" or "good" using mean or median cutoffs depending on distribution. Logistic regression was applied to explore associations between participant characteristics and KAP outcomes.

Read the detailed description

Tuberculosis (TB) continues to pose a significant global health burden, particularly among individuals in the economically productive age group of 15-64 years. In Zambia, 85% of TB cases occur in this demographic, underscoring the dual public health and socio-economic impact. The risk is compounded in industries with high exposure to crystalline silica dust, such as mining, construction, drilling, cement, brick, tile, glass, and ceramics manufacturing. Prolonged inhalation of silica dust can lead to silicosis, a condition that increases the risk of TB three to four times compared to individuals without silicosis. Even without silicosis, silica exposure alone elevates TB risk. Poor workplace conditions, including overcrowding and inadequate ventilation, further exacerbate transmission risks.

Recognizing these occupational hazards, the study aimed to assess the knowledge, attitudes, and practices (KAP) of senior management officials in companies with high silica exposure. These officials play a critical role in shaping workplace policies and interventions, making their understanding and attitudes toward TB prevention and management essential for effective workplace health strategies.

The research was conducted as a descriptive cross-sectional study between February and October 2022 in Lusaka and Southern provinces of Zambia. These provinces were selected due to their concentration of industries associated with silica dust exposure. The study focused on senior management officials, defined as either the most senior staff in an organization or heads of divisions/departments, given their influence on workplace health policies.

The sample population was drawn from the Zambia Chamber of Commerce and Industry (ZACCI), an umbrella organization representing businesses across all sectors. ZACCI advocates for workplace legislation and a conducive business environment. Companies known to produce silica dust were identified under categories including mining, construction, cement manufacturing, brick and tile manufacturing, and glass and ceramic manufacturing. The sampling frame included 1 mining company, 73 construction companies, 1 cement company, 9 brick/tile companies, and 10 glass/ceramic companies.

Each company was asked to nominate at least one senior official to complete the questionnaire, with a maximum of two responses per company. This ensured representation across industries while maintaining focus on individuals with policy-making authority.

Data were collected using a multiple-choice electronic questionnaire developed in accordance with WHO guidelines for TB KAP surveys. The questionnaire was self-administered in English via Google Forms and contained 28 mandatory closed-ended questions:

  • Knowledge: 7 questions
  • Attitudes: 8 questions
  • Practices: 13 questions (with 5 excluded from scoring as they were programmatic) Of the 28 questions, 21 were multiple-choice, while 7 required a single best answer. The questionnaire was distributed via email, with three reminders sent to encourage participation. Due to low response rates from email reminders, physical follow-ups were conducted. Ultimately, participants completed the survey independently on tablets between June and November 2022.

Responses were validated by three medical doctors. A response was considered correct if at least two doctors agreed. This ensured accuracy and minimized bias in scoring. Responses marked as "don't know," "not sure," or "other" were treated neutrally with a score of 0. Ambiguous "other" responses were excluded from analysis.

Survey responses were stored on Google Forms, downloaded into a CSV file, and imported into Python (version 3.8) for recoding. The dataset was then analyzed using STATA (version 18.5). Descriptive statistics were used to summarize participant characteristics and categorical variables.

A scoring system was applied:

  • Knowledge: maximum of 17 points
  • Attitudes: maximum of 7 points
  • Practices: maximum of 14 points Correct responses scored 1, incorrect responses scored 0. Scores were categorized into "poor" or "good" based on mean or median cutoffs depending on distribution. Logistic regression was used to explore associations between participant characteristics (age, gender, industry, department) and KAP outcomes. Univariable analysis identified potential associations, followed by multivariable analysis to control for confounders. Variables with p-values above 0.05 were excluded unless only two variables remained significant, in which case the higher p-value variable was retained.
Keywords
TB, Tuberculosis, Knowledge, Attitude, Practice, Senior management, Silicosis, Silica Dust, non mining companies
Medical subject headings
Latent Tuberculosis, Silicosis, Tuberculosis, Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07749872
Study groupRoleWhat they receive
Senior management from companies known to produce silica dustCategories including mining, construction, cement manufacturing, brick and tile manufacturing, and glass and ceramic manufacturing.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Knowledge, attitudes, and practices (KAP) scores related to tuberculosis among senior management of manufacturing, construction, and mining companies associated with exposure to silica dust.

    Descriptive Cross - sectional study

    Measured: Conducted between February 2022 to October 2022

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Aug 2026
  2. Study start2 Feb 2022
  3. Primary completion15 Oct 2022
  4. Study completion28 Feb 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
118 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07749872
Sponsor's protocol ID
2327-2021 KAP TB
Other IDs
72061120CA00001
Acronym
KAP TB
Status last verified
Aug 2026
First submitted
31 Jul 2026
Last updated
6 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of TB - Tuberculosis and Silicosis, run by Centre for Infectious Disease Research in Zambia at 1 site in Zambia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Zambia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Knowledge, attitudes, and practices (KAP) scores related to tuberculosis among senior management of manufacturing, construction, and mining companies associated with exposure to silica dust. (time frame: Conducted between February 2022 to October 2022). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in